Headlines

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia

A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

Nonmyeloablative/Reduced-Intensity Conditioning May Reduce Mucositis in HCT

Researchers sought to determine if NMA or reduced-intensity conditioning with busulfan improved severity/duration of oral mucositis compared with myeloablative conditioning in patients with hematologic cancer undergoing HCT.

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis

In a phase 2 study, researchers assessed the efficacy of using a dose-escalation approach to lessen the occurrence and severity of anemia in MF treated with ruxolitinib.

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera

In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma

The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

8 Hours of Bedrest May Be Ideal After Intrathecal Chemotherapy in Hematologic Cancers

In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.

Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer

Adding Bevacizumab to First-line Chemotherapy Benefits Selects Cases of Ovarian Cancer

Researchers conducted a retrospective analysis to determine the impact of inflammatory responses in patients with ovarian cancer undergoing first-line chemotherapy with or without bevacizumab.

Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma

Assessing Direct Costs of Treatment-Related Adverse Events in Advanced Melanoma

In a systematic review, researchers explored the financial burden of treating grade 3 to 4 adverse events associated with melanoma and its treatment.

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

Health Domains May Mediate Psychological Risk in Survivors of Childhood Leukemia

A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Conference Coverage

Lung Cancer: What Nurse Navigators Need to Know in 2018

There have been many recent changes in lung cancer, including updated early detection possibilities and changes in diagnostic procedures, reporting, and treatment options. These are reviewed in a presentation at the 2018 ONA Navigation Summit.

Navigating Patients with Hematologic Malignancies

Patients with hematologic cancers often require a combination of inpatient and outpatient care. The oncology nurse navigator is an ideal care provider to help patients manage their care and transitions between care settings, according to a presentation at the 2018 ONA Navigation Summit.

Navigating the Benefits and Challenges of Immunotherapy

A review of immunotherapy — what they are, how they work, and what to watch for — was presented at the 2018 ONA Navigation Summit.

Difficult Conversations: The Role of Nurse Navigator

Suggestions for communication points that improve the experience of patients with cancer through nurse navigation were presented at the 2018 ONA Navigation Summit.

Navigating Patients With Gastrointestinal Cancer

The unique challenges that face both oncology nurse navigators specializing in gastrointestinal cancer and patients with these diseases are reviewed in a presentation at the 2018 ONA Navigation Summit.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs